Literature DB >> 20921333

Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease.

Maarten F Corsten1, Robert Dennert, Sylvia Jochems, Tatiana Kuznetsova, Yvan Devaux, Leon Hofstra, Daniel R Wagner, Jan A Staessen, Stephane Heymans, Blanche Schroen.   

Abstract

BACKGROUND: Small RNA molecules, called microRNAs, freely circulate in human plasma and correlate with varying pathologies. In this study, we explored their diagnostic potential in a selection of prevalent cardiovascular disorders. METHODS AND
RESULTS: MicroRNAs were isolated from plasmas from well-characterized patients with varying degrees of cardiac damage: (1) acute myocardial infarction, (2) viral myocarditis, (3) diastolic dysfunction, and (4) acute heart failure. Plasma levels of selected microRNAs, including heart-associated (miR-1, -133a, -208b, and -499), fibrosis-associated (miR-21 and miR-29b), and leukocyte-associated (miR-146, -155, and -223) candidates, were subsequently assessed using real-time polymerase chain reaction. Strikingly, in plasma from acute myocardial infarction patients, cardiac myocyte-associated miR-208b and -499 were highly elevated, 1600-fold (P<0.005) and 100-fold (P<0.0005), respectively, as compared with control subjects. Receiver operating characteristic curve analysis revealed an area under the curve of 0.94 (P<10(-10)) for miR-208b and 0.92 (P<10(-9)) for miR-499. Both microRNAs correlated with plasma troponin T, indicating release of microRNAs from injured cardiomyocytes. In viral myocarditis, we observed a milder but significant elevation of these microRNAs, 30-fold and 6-fold, respectively. Plasma levels of leukocyte-expressed microRNAs were not significantly increased in acute myocardial infarction or viral myocarditis patients, despite elevated white blood cell counts. In patients with acute heart failure, only miR-499 was significantly elevated (2-fold), whereas no significant changes in microRNAs studied could be observed in diastolic dysfunction. Remarkably, plasma microRNA levels were not affected by a wide range of clinical confounders, including age, sex, body mass index, kidney function, systolic blood pressure, and white blood cell count.
CONCLUSIONS: Cardiac damage initiates the detectable release of cardiomyocyte-specific microRNAs-208b and -499 into the circulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921333     DOI: 10.1161/CIRCGENETICS.110.957415

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  299 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  Routine invasive versus conservative management in non-ST-elevation acute coronary syndromes.

Authors:  Peter R Sinnaeve
Journal:  J Cardiovasc Transl Res       Date:  2011-11-01       Impact factor: 4.132

Review 3.  Circulating microRNAs: novel biomarkers for cardiovascular diseases.

Authors:  Jiahong Xu; Jiangmin Zhao; Graham Evan; Chunyang Xiao; Yan Cheng; Junjie Xiao
Journal:  J Mol Med (Berl)       Date:  2011-12-08       Impact factor: 4.599

Review 4.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

Review 5.  Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators.

Authors:  Zhuzhi Wen; Shaoxin Zheng; Changqing Zhou; Woliang Yuan; Jingfeng Wang; Tong Wang
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

Review 6.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 7.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

Review 8.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

9.  Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport.

Authors:  Nnenna A Finn; Danny Eapen; Pankaj Manocha; Hatem Al Kassem; Bernard Lassegue; Nima Ghasemzadeh; Arshed Quyyumi; Charles D Searles
Journal:  FEBS Lett       Date:  2013-09-13       Impact factor: 4.124

10.  Circulating miRNA as novel markers for diastolic dysfunction.

Authors:  Nandini Nair; Sandeep Kumar; Enrique Gongora; Sudhiranjan Gupta
Journal:  Mol Cell Biochem       Date:  2012-12-18       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.